Study of Addition of Panitumumab to Chemoradiation Therapy in Patients with Locally Advanced Head and Neck Cancer

- Confirmed diagnosis of Stage III or IVa-b (M0) squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (you must be well enough to receive chemoradiation therapy) - You must be at least 18 years of age - Your test results must show that your kidneys, liver and blood cells are working adequately and that, if you are female, you are not pregnant - You must have measurable disease

- Cancer of the nasopharynx, sinus, salivary gland or skin - History of another cancer (other than head and neck) unless treated with curative intent and with no evidence of disease for more than 3 years, with the exception of non-melanoma skin cancer or in situ cervical cancer - Previous treatment with anti-endothelial growth factor receptor (EGFr) antibody therapy or EGFr inhibitors - Previous treatment for head and neck cancer, with chemotherapy, surgery (except nodal sampling or biopsy) or radiotherapy - Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within one year before you join the study - Chronic obstructive pulmonary disease (pneumonia or respiratory decompensation) resulting in hospitalization within 6 months of study screening - History or evidence of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) - Major surgery within 28 days of screening